Reading Seminars on Health Innovation
These interdisciplinary seminars represent a new step in the development of the I3h Institute, which is now co-directed by Michel Goldman and Mathias Dewatripont. The objective is to stimulate interdisplinary research and reflections about the multiple challenges that healthcare is facing. The participation in the seminar is free of charge. Future sessions will focus on presentations of participants’ own work or of other work deemed particularly relevant for the topic.
If you would like to be included in the e-mail list, please contact awozniak@i3health.eu.
Upcoming seminars
- October 29, 2018 - 13:00 to 15:00
- ULB Solbosch Building H room H.3.366 Brussels
- Towards new partnerships in the healthcare sector
Wim Van Haverbeke Professor of Innovation Management & Strategy at the Hasselt University
- November 12, 2018 - 13:00 to 15:00
- ULB Solbosch Building H room H.3.366 Brussels
- Market definition in the pharmaceutical industry: a case of drugs hopping antitrust markets
Georges Siotis Associate Professor at the Economics Department of Universidad Carlos III de Madrid and CEPR Research Fellow
- November 26, 2018 - 13:00 to 15:00
- ULB Solbosch Building H room H.3.366 Brussels
- Precision oncology: how to structure the continuum of clinical research into healthcare for rationale access to anti-cancer treatment
Denis Lacombe Director General of the European Organisation for Research and Treatment of Cancer
- November 30, 2018 - 13:00 to 15:00
- The case of a multi-drug resistant infection
Hospital Erasme
- December 10, 2018 - 13:00 to 15:00
- ULB Solbosch Building H room H.3.366 Brussels
- Scientific, regulatory, and economic challenges facing the implementation of phage therapy and the Belgian model.
Bob Blasdel Research Director for Vesale Pharma
Previous seminars
- October 08, 2018
- Vaccines: how to value them, how to price them?
Michel Dewilde MDWConsultant, former Senior Vice President R&D, Sanofi Pasteur
- October 01, 2018
- Measuring mortality in conflicts and disasters: why does it matter?
Debarati Guha Director of the Centre for Research on the Epidemiology of Disasters (CRED) and Professor at the School of Public Health (UCL)
- June 04, 2018
- Public funding and influential health research: Evidence from the US and the UK
Charitini Stavropoulou Senior Lecturer in Health Management at the School of Health Sciences (City University of London)
- May 28, 2018
- Endogenous childlessness and stages of development
Paula E. Gobbi Member of ECARES (ULB) and CEPR
- May 07, 2018
- Translational hepatology: scientific, economic and financial challenges
Etienne Sokal Professor at UCLouvain, Hepatologist at Cliniques Universitaires Saint Luc and Founder of Promethera Biosciences
- April 23, 2018
- Novel approaches to pricing and reimbursement for innovative medicines
Lieven Annemans Professor of Health Economics at the Medical Faculty of Ghent University
- April 09, 2018
- Value assessment and reimbursement: the (special?) case of orphan drugs
Steven Simoens Professor at the Faculty of Pharmaceutical Sciences (KU Leuven)
- March 19, 2018
- Subgroup and post-hoc analyses in clinical trials: the truth lies in the eye of the beholder
Bruno Flamion MD, PhD, Professor of Clinical Pharmacology (UNamur) and VP Head Strategic Development (Idorsia Pharmaceuticals)
- March 05, 2018
- Are ideas getting harder to find?
Øyvind Aas Post-doctoral researcher at ECARES, ULB
- February 26, 2018
- Economic value of vaccines for the developing world: different perspectives
Bill Hausdorff Senior Lecturer at Faculté de Médecine ULB, Independent Consultant